{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yu A"],"funding":["Hunan Natural Science Foundation","National Natural Science Foundation of China","Guangzhou Science and Technology Projects","Hunan Province Young Talents Program","the Natural Science Foundation of Guangdong Province, China"],"pagination":["e007230"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10565151"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(10)"],"pubmed_abstract":["<h4>Background</h4>Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The leucine-rich repeat and fibronectin type-III domain-containing protein (LRFN) family has previously been implicated in regulating brain dysfunction; however, the mechanisms underlying the effect of LRFN2 on the tumor microenvironment (TME) and immunotherapy remain unclear.<h4>Methods</h4>Here we combined bulk RNA sequencing, single-cell RNA sequencing, ProcartaPlex multiple immunoassays, functional experiments, and TissueFAXS panoramic tissue quantification assays to demonstrate that LRFN2 shapes a non-inflammatory TME in BLCA.<h4>Results</h4>First, com"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8<sup>+</sup> T cell infiltration and functional transition."],"pmcid":["PMC10565151"],"funding_grant_id":["81902576","82103639","2023A1515030038","82070785","202201010910","2020JJ5884","81873626","2021RC3027","81902592"],"pubmed_authors":["Li H","Shu G","Jing L","Huang G","Zhang M","Deng D","Hu J","Chen Z","Luo J","Yu A","Zu X","Fu L","Chen X","Wang Y","Yang T","Wei J"],"additional_accession":[]},"is_claimable":false,"name":"Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8<sup>+</sup> T cell infiltration and functional transition.","description":"<h4>Background</h4>Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The leucine-rich repeat and fibronectin type-III domain-containing protein (LRFN) family has previously been implicated in regulating brain dysfunction; however, the mechanisms underlying the effect of LRFN2 on the tumor microenvironment (TME) and immunotherapy remain unclear.<h4>Methods</h4>Here we combined bulk RNA sequencing, single-cell RNA sequencing, ProcartaPlex multiple immunoassays, functional experiments, and TissueFAXS panoramic tissue quantification assays to demonstrate that LRFN2 shapes a non-inflammatory TME in BLCA.<h4>Results</h4>First, com","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-06-15T06:34:15.476Z","creation":"2025-02-18T23:52:21.817Z"},"accession":"S-EPMC10565151","cross_references":{"pubmed":["37802603"],"doi":["10.1136/jitc-2023-007230"]}}